POLB 001
Prevention of Cancer Immunotherapy-Induced Cytokine Release Syndrome (CRS)
Phase 1b/2Active - TOPICAL trial ongoing
Key Facts
Indication
Prevention of Cancer Immunotherapy-Induced Cytokine Release Syndrome (CRS)
Phase
Phase 1b/2
Status
Active - TOPICAL trial ongoing
Company
About Poolbeg Pharma
Poolbeg Pharma is a UK-based, AIM-listed biotech founded in 2021 with a mission to develop high-value therapies for large markets with unmet needs. Its strategy centers on a capital-efficient model of de-risking assets through early clinical development before pursuing partnerships. Key achievements include securing FDA Orphan Drug Designation for its lead oncology asset, POLB 001, and building a proprietary AI discovery platform powered by unique human challenge trial data. The company aims to accelerate pipeline growth while minimizing substantial capital expenditure.
View full company profile